In a press release issued March 8th it was announced that Health Canada has approved the use of Ibutrinib in combination with rituximab for both first and later lines of treatment for patients of Waldenstroms Macroglobulinemia.
The release has been… Continue reading
Patients with symptomatic Waldenström macroglobulinemia (WM) benefit from first-line treatment with ibrutinib, which Steven P. Treon, MD, PhD, Bing Center for Waldenström Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, and colleagues describe as being highly active and safe… Continue reading
A head-to-head, open-label, multicenter, phase 3 clinical trial comparing the efficacy and safety of zanubrutinib (BGB-3111) with ibrutinib in patients with Waldenström macroglobulinemia (WM) is underway (ClinicalTrials.org Identifier: NCT03053440).1 The study also seeks to evaluate the… Continue reading
This morning, August 27, 2018, the US Food and Drug Administration (FDA) approved ibrutinib (IMBRUVICA, AbbVie) in combination with rituximab (RITUXAN) for the treatment of Waldenström’s macroglobulinemia. This combination is the first and only chemotherapy-free treatment option for patients with… Continue reading
Meletios Dimopoulos, MD, professor and chairman, Department of Clinical Therapeutics at the University of Athens School of Medicine, Athens, Greece, discusses the impact of the results from the iNNOVATE study of ibrutinib (Imbruvica) plus rituximab (Rituxan) in patients… Continue reading
Author(s): Paludo J, Ansell SM
Abstract: Waldenström macroglobulinemia (WM) is a distinct clinicopathologic entity characterized by the presence of a lymphoplasmacytic lymphoma, a non-Hodgkin lymphoma, and IgM monoclonal gammopathy. WM is an indolent, uncommon… Continue reading